Correction on Medtronic’s InterStim neurostimulator
This article was originally published in The Gray Sheet
Executive Summary
The sacral nerve neurostimulation implant, for which Medtronic recently submitted a PMA application for treatment of fecal incontinence, was originally approved in 1997 for urinary incontinence. "The Gray Sheet" had erroneously reported that the urinary indication was first approved in 2006 (1"The Gray Sheet" Oct. 27, 2008, In Brief)
You may also be interested in...
Medtronic InterStim
Firm submits a PMA application for treatment of fecal incontinence with the neurostimulation implant, anticipating a U.S. launch in 2009, Medtronic announces Oct. 22. The device, which works by stimulating the sacral nerve, has been approved since 2006 for urinary incontinence (1"The Gray Sheet" July 10, 2006, In Brief)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.